147 filings
8-K
ONCSQ
ONCOSEC MEDICAL Inc
22 Jun 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
8:30am
8-K
ONCSQ
ONCOSEC MEDICAL Inc
14 Jun 23
Bankruptcy or Receivership
5:20pm
8-K
ONCSQ
ONCOSEC MEDICAL Inc
14 Jun 23
Departure of Directors or Certain Officers
4:55pm
8-K
ONCSQ
ONCOSEC MEDICAL Inc
2 Jun 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
5:00pm
8-K
ONCSQ
ONCOSEC MEDICAL Inc
18 May 23
OncoSec Announces $1.33 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
4:35pm
8-K
z04vum j39hu
16 May 23
OncoSec is encouraged after FDA meeting to discuss proposed neoadjuvant melanoma clinical program
8:15am
8-K
ywn4x12jjcf 9zoh
27 Apr 23
Other Events
8:00am
8-K
89mlq5vast5z
11 Apr 23
OncoSec Announces $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
4:05pm
8-K
1kh0bzee6hrv1 lkl
3 Apr 23
Other Events
7:30am
8-K
hvki1
22 Feb 23
Other Events
8:30am
8-K
y84bsl50zv72rv
4 Jan 23
Amendments to Articles of Incorporation or Bylaws
4:10pm
8-K
447809u2rfim
28 Dec 22
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
5:00pm
8-K
4f2782 6ew6x9gur6
27 Dec 22
Departure of Directors or Certain Officers
5:00pm
8-K
8j2562
1 Dec 22
OncoSec Announces Pricing of $3.5 Million Public Offering
4:57pm
8-K
apf d1428
29 Nov 22
Entry into a Material Definitive Agreement
8:00am
8-K
5agqnqajaqrpkrr
22 Nov 22
Other Events
5:00pm
8-K
2h3i7oyq
15 Nov 22
OncoSec presents encouraging early data with TAVO™-EP combined with nivolumab (Opdivo®) in neoadjuvant melanoma
5:06pm
8-K
9y6ndu3l
14 Nov 22
Other Events
6:10am
8-K
1l1qruh 58kzg4fmo2
8 Nov 22
OncoSec Announces Reverse Stock Split
1:15pm
8-K
neqwewgva9
17 Oct 22
Departure of Directors or Certain Officers
5:00pm